AR091413A1 - Formulacion de anticuerpos - Google Patents
Formulacion de anticuerposInfo
- Publication number
- AR091413A1 AR091413A1 ARP130102057A AR091413A1 AR 091413 A1 AR091413 A1 AR 091413A1 AR P130102057 A ARP130102057 A AR P130102057A AR 091413 A1 AR091413 A1 AR 091413A1
- Authority
- AR
- Argentina
- Prior art keywords
- aqueous composition
- antibody
- composition according
- delivery device
- filled syringe
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los anticuerpos anti-BAFFR se formulan como formulación líquida que comprende una alta concentración del ingrediente activo de anticuerpo para la entrega en un paciente sin altos niveles de agregación de anticuerpos. La composición farmacéutica acuosa puede incluir uno o más azúcares, un agente amortiguador, un surfactante, y/o un aminoácido libre. Reivindicación 2: La composición acuosa de la reivindicación 1 que tiene un pH de 5.5 - 6.5 y que comprende (i) un anticuerpo anti-BAFFR en el que el anticuerpo tiene una concentración de 18 a -165 mg/ml, y en el que dicho anticuerpo anti-BAFFR incluye CDR1, CDR2 y CDR3 de cadena pesada de SEC ID Nº 3, 4 y 5, respectivamente, y CDR1, CDR2 y CDR3 de cadena ligera de SEC ID Nº 6, 7 y 8, (ii) sacarosa, trehalosa o manitol como un estabilizador, (iii) histidina, citrato o succinato como un agente amortiguador, (iv) polisorbato 20, poloxámero 188 o hidroxipropil-b-ciclodextrina como un surfactante, y, opcionalmente, (v) arginina como un aminoácido. Reivindicación 25: Un dispositivo de suministro que comprende la composición acuosa de acuerdo con una cualquiera de las reivindicaciones 1 - 24. Reivindicación 26: Un jeringa pre-cargada que comprende la composición acuosa de acuerdo con una cualquiera de las reivindicaciones 1 - 24. Reivindicación 30: La composición acuosa según una cualquiera de las reivindicaciones 1 - 24, o el dispositivo de administración de la reivindicación 25, o la jeringa pre-cargada de la reivindicación 26, para su utilizar en el tratamiento de un neoplasma de células B, tal como linfoma, leucemia o mieloma. Reivindicación 31: La composición acuosa según una cualquiera de las reivindicaciones 1 - 24, o el dispositivo de administración de la reivindicación 25, o la jeringa pre-cargada de la reivindicación 26, para su utilizar en el tratamiento de artritis reumatoide, lupus eritematoso sistémico, síndrome de Sjögren, o pénfigo vulgar.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261658472P | 2012-06-12 | 2012-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091413A1 true AR091413A1 (es) | 2015-02-04 |
Family
ID=48914378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102057 AR091413A1 (es) | 2012-06-12 | 2013-06-12 | Formulacion de anticuerpos |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US9216219B2 (es) |
| EP (2) | EP2858671B1 (es) |
| JP (1) | JP6265978B2 (es) |
| KR (1) | KR102124820B1 (es) |
| CN (1) | CN104363920B (es) |
| AR (1) | AR091413A1 (es) |
| AU (1) | AU2013276112B2 (es) |
| BR (1) | BR112014030820B1 (es) |
| CA (1) | CA2875386C (es) |
| CL (1) | CL2014003370A1 (es) |
| CO (1) | CO7151487A2 (es) |
| CY (1) | CY1122181T1 (es) |
| DK (1) | DK2858671T3 (es) |
| EA (1) | EA033373B1 (es) |
| EC (1) | ECSP15017314A (es) |
| ES (1) | ES2751659T3 (es) |
| GT (1) | GT201400285A (es) |
| HK (1) | HK1203146A1 (es) |
| HR (1) | HRP20191827T1 (es) |
| HU (1) | HUE045523T2 (es) |
| IL (1) | IL235966B (es) |
| LT (1) | LT2858671T (es) |
| MA (1) | MA37616A1 (es) |
| MX (1) | MX363380B (es) |
| MY (1) | MY179818A (es) |
| NZ (1) | NZ630885A (es) |
| PE (1) | PE20150200A1 (es) |
| PH (1) | PH12014502778A1 (es) |
| PL (1) | PL2858671T3 (es) |
| PT (1) | PT2858671T (es) |
| SG (1) | SG11201408174UA (es) |
| SI (1) | SI2858671T1 (es) |
| TN (1) | TN2014000488A1 (es) |
| TW (1) | TWI653983B (es) |
| WO (1) | WO2013186700A1 (es) |
| ZA (1) | ZA201408547B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2521568T (lt) | 2010-01-06 | 2018-12-10 | Dyax Corp. | Plazmos kalikreiną surišantys baltymai |
| WO2012076670A2 (en) * | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| CN105713092B (zh) | 2011-01-06 | 2019-09-10 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗ｍｃａｍ抗體及相關使用方法 |
| WO2014152232A2 (en) | 2013-03-15 | 2014-09-25 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| CN104730237A (zh) * | 2013-12-23 | 2015-06-24 | 国家纳米科学中心 | 试纸及其应用以及检测甲胎蛋白抗原、乙肝表面抗原或HIV的gp41抗体的方法 |
| WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| KR20160127825A (ko) | 2014-03-12 | 2016-11-04 | 프로테나 바이오사이언시즈 리미티드 | 항-mcam 항체 및 관련된 사용 방법 |
| KR101597037B1 (ko) | 2014-06-26 | 2016-02-24 | 엘지디스플레이 주식회사 | 구동소자의 전기적 특성 편차를 보상할 수 있는 유기발광 표시장치 |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| IL305207A (en) * | 2015-03-30 | 2023-10-01 | Takeda Pharmaceuticals Co | Plasma kallikrein inhibitors and their uses to prevent the outbreak of hereditary angioedema |
| JP2018530540A (ja) * | 2015-09-16 | 2018-10-18 | プロセナ バイオサイエンシーズ リミテッド | 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗ｍｃａｍ抗体の使用 |
| US11058769B2 (en) * | 2015-12-07 | 2021-07-13 | Merck Patent Gmbh | Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab |
| AU2016366557B2 (en) | 2015-12-11 | 2024-01-25 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| SG11201805123XA (en) * | 2015-12-18 | 2018-07-30 | Astellas Pharma Inc | Pharmaceutical composition comprising anti-human tslp receptor antibody |
| BR112018075785A2 (pt) * | 2016-06-16 | 2019-04-02 | Janssen Vaccines & Prevention B.V. | formulação de vacina para o hiv |
| CA3041254A1 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
| KR102312222B1 (ko) | 2016-12-22 | 2021-10-12 | 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 | Ｃｄ43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체 |
| CN110366429A (zh) * | 2017-03-01 | 2019-10-22 | 免疫医疗有限公司 | 单克隆抗体的配制品 |
| AU2018229724A1 (en) * | 2017-03-06 | 2019-10-31 | Merck Patent Gmbh | Aqueous anti-PD-L1 antibody formulation |
| WO2018193471A1 (en) * | 2017-04-18 | 2018-10-25 | Dr. Reddy's Laboratories Limited | Stable liquid pharmaceutical composition |
| JP7079844B2 (ja) * | 2017-07-27 | 2022-06-02 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 高濃度抗ｃ５抗体製剤 |
| CA3073066A1 (en) * | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| BR112020010483A2 (pt) * | 2017-11-29 | 2020-10-20 | Prothena Biosciences Limited | formulação liofilizada de um anticorpo monoclonal contra transtirretina |
| CA3102349A1 (en) | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
| JOP20210152A1 (ar) * | 2018-12-18 | 2023-01-30 | Novartis Ag | صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf |
| CA3129901A1 (en) | 2019-02-18 | 2020-08-27 | Eli Lilly And Company | Therapeutic antibody formulation |
| JP2022521624A (ja) * | 2019-02-26 | 2022-04-11 | イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド | 抗ｃｄ４７抗体を含む製剤、その調製方法および使用 |
| JP2023501781A (ja) | 2019-11-06 | 2023-01-19 | ノバルティス アーゲー | シェーグレン症候群の処置 |
| WO2021136274A1 (zh) * | 2019-12-30 | 2021-07-08 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
| CA3168600A1 (en) * | 2020-01-21 | 2021-07-29 | Innovent Biologics (Suzhou) Co., Ltd. | Recombinant fully human anti-tigit monoclonal antibody formulation, method for preparing same and use thereof |
| IL300086A (en) | 2020-08-04 | 2023-03-01 | Novartis Ag | Treatment of B-cell malignancies |
| CN115073598B (zh) * | 2021-03-15 | 2024-02-20 | 盛禾(中国)生物制药有限公司 | 一种抗baffr抗体及其应用 |
| CN117203240A (zh) | 2021-05-04 | 2023-12-08 | 诺华股份有限公司 | 使用抗baffr抗体治疗狼疮肾炎 |
| EP4334351A1 (en) | 2021-05-04 | 2024-03-13 | Novartis AG | Treatment for systemic lupus erythematosus using anti-baffr antibodies |
| TW202330604A (zh) * | 2021-09-29 | 2023-08-01 | 美商蜻蜓醫療公司 | 靶向ｂａｆｆ—ｒ的抗體及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| WO1990006952A1 (en) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US20020077461A1 (en) * | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
| WO2000078930A1 (en) | 1999-06-23 | 2000-12-28 | Oregon Health Sciences University | Method for enhancing hematopoiesis |
| WO2002000879A2 (en) | 2000-06-28 | 2002-01-03 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| ATE556591T1 (de) | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
| EP3210624A1 (en) | 2002-02-27 | 2017-08-30 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| WO2004055164A2 (en) | 2002-12-13 | 2004-07-01 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EA200701211A1 (ru) * | 2004-12-31 | 2007-12-28 | Дженентек, Инк. | Полипептиды, которые связываются с br3, и их применение |
| DK2315780T3 (en) * | 2008-07-17 | 2015-10-19 | Novartis Ag | Compositions and methods for the use of therapeutic antibodies |
| CN102665691B (zh) * | 2009-11-17 | 2015-05-27 | 益普生制药股份有限公司 | hGH和rhIGF-1组合的制剂 |
| WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| US20140335084A1 (en) | 2011-12-06 | 2014-11-13 | Hoffmann-La Roche Inc. | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
-
2013
- 2013-06-07 US US13/912,355 patent/US9216219B2/en active Active
- 2013-06-10 MA MA37616A patent/MA37616A1/fr unknown
- 2013-06-11 SI SI201331596T patent/SI2858671T1/sl unknown
- 2013-06-11 EP EP13744818.9A patent/EP2858671B1/en active Active
- 2013-06-11 JP JP2015516723A patent/JP6265978B2/ja active Active
- 2013-06-11 CA CA2875386A patent/CA2875386C/en active Active
- 2013-06-11 SG SG11201408174UA patent/SG11201408174UA/en unknown
- 2013-06-11 NZ NZ630885A patent/NZ630885A/en not_active IP Right Cessation
- 2013-06-11 PE PE2014002437A patent/PE20150200A1/es not_active Application Discontinuation
- 2013-06-11 EA EA201492292A patent/EA033373B1/ru not_active IP Right Cessation
- 2013-06-11 LT LT13744818T patent/LT2858671T/lt unknown
- 2013-06-11 HU HUE13744818A patent/HUE045523T2/hu unknown
- 2013-06-11 DK DK13744818.9T patent/DK2858671T3/da active
- 2013-06-11 PT PT137448189T patent/PT2858671T/pt unknown
- 2013-06-11 PL PL13744818T patent/PL2858671T3/pl unknown
- 2013-06-11 MX MX2014015262A patent/MX363380B/es unknown
- 2013-06-11 KR KR1020157000336A patent/KR102124820B1/ko active IP Right Grant
- 2013-06-11 TW TW102120795A patent/TWI653983B/zh active
- 2013-06-11 WO PCT/IB2013/054777 patent/WO2013186700A1/en active Application Filing
- 2013-06-11 ES ES13744818T patent/ES2751659T3/es active Active
- 2013-06-11 AU AU2013276112A patent/AU2013276112B2/en active Active
- 2013-06-11 MY MYPI2014703690A patent/MY179818A/en unknown
- 2013-06-11 BR BR112014030820-9A patent/BR112014030820B1/pt active IP Right Grant
- 2013-06-11 EP EP19185836.4A patent/EP3593814A1/en active Pending
- 2013-06-11 CN CN201380031181.8A patent/CN104363920B/zh active Active
- 2013-06-12 AR ARP130102057 patent/AR091413A1/es not_active Application Discontinuation
-
2014
- 2014-11-20 ZA ZA2014/08547A patent/ZA201408547B/en unknown
- 2014-11-21 TN TN2014000488A patent/TN2014000488A1/fr unknown
- 2014-11-27 IL IL235966A patent/IL235966B/en active IP Right Grant
- 2014-12-11 CL CL2014003370A patent/CL2014003370A1/es unknown
- 2014-12-11 PH PH12014502778A patent/PH12014502778A1/en unknown
- 2014-12-11 GT GT201400285A patent/GT201400285A/es unknown
- 2014-12-18 CO CO14278419A patent/CO7151487A2/es unknown
-
2015
- 2015-01-12 EC ECIEPI201517314A patent/ECSP15017314A/es unknown
- 2015-04-15 HK HK15103657.1A patent/HK1203146A1/xx unknown
- 2015-11-16 US US14/942,388 patent/US9751951B2/en active Active
-
2017
- 2017-08-31 US US15/692,490 patent/US20180051092A1/en not_active Abandoned
-
2018
- 2018-05-15 US US15/980,411 patent/US10689451B2/en active Active
-
2019
- 2019-10-09 HR HRP20191827TT patent/HRP20191827T1/hr unknown
- 2019-10-22 CY CY20191101096T patent/CY1122181T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091413A1 (es) | Formulacion de anticuerpos | |
| CO7111300A2 (es) | Formulación de anticuerpos | |
| JP2015521593A5 (es) | ||
| CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
| AR064826A1 (es) | Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa | |
| EA201492290A1 (ru) | Составы и способы для вагинальной доставки антипрогестинов | |
| WO2012076670A3 (en) | Antibody formulation | |
| AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
| ECSP21043639A (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| MX2019014666A (es) | Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo. | |
| PE20191550A1 (es) | COMPOSICION FARMACEUTICA ACUOSA DE ANTICUERPO MONOCLONAL ANTI-TNFalfa RECOMBINANTE | |
| PE20160850A1 (es) | Sistema multiparticulado para administrar drogas | |
| PE20171061A1 (es) | Composiciones farmaceuticas de accion prolongada para hepatitis c | |
| AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| JO3689B1 (ar) | صيغ من الباراسيتامول قابلة للحقن | |
| TH125691B (th) | สูตรของแอนดี้บอดี้ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |